Ergebnisse der zulassungsrelevanten Phase-3-Studie „frontMIND“ von Incyte zur Kombination von Tafasitamab (Monjuvi® /Minjuvi® ), die auf der Plenarsitzung des Kongresses der European Hematology Association (EHA) 2026 vorgestellt wurden...

Key Takeaway: Incyte presented results from the Phase 3 study 'frontMIND' regarding Tafasitamab (Monjuvi/Minjuvi) at the European Hematology Association Congress 2026. The study's findings are expected to contribute to the understanding of Tafasitamab's efficacy in combination therapy. Further details on the results were not provided in the article.